Key result
High-intensity statins were associated with a lower risk for net adverse clinical and cerebral events compared to no statin therapy (HR 0.51; 95% CI 0.40-0.66).
Why the study?
Does statin therapy reduce net adverse clinical and cerebral events in patients with acute ischemic stroke and atrial fibrillation?
Population
2153 patients with acute ischemic stroke and atrial fibrillation
Comparison
Low- to moderate-intensity statins vs high-intensity statins vs no statin therapy
Design
Nationwide multicenter cohort study
Follow-up
3-year period
Authors
Loading...
May support statin use in acute ischemic stroke with AF; leaves open confirmation in randomized trials.
Cohort (n=2,153)
Yes
Does statin therapy reduce net adverse clinical and cerebral events in patients with acute ischemic stroke and atrial fibrillation?
Hazard Ratio: 0.51 (95% CI 0.4–0.66)
In patients with acute ischemic stroke and atrial fibrillation, statin therapy, particularly high-intensity statins, is associated with a significantly reduced risk of net adverse clinical and cerebral events over 3 years.
Choi et al. (2019) conducted a cohort in Acute ischemic stroke and atrial fibrillation (n=2,153). Statin therapy vs. No statin therapy was evaluated on Net adverse clinical and cerebral events (NACCE; death from any cause, stroke, acute coronary syndrome, or major bleeding) (HR 0.51, 95% CI 0.40-0.66). High-intensity statins were associated with a lower risk for net adverse clinical and cerebral events compared to no statin therapy (HR 0.51; 95% CI 0.40-0.66).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: